Centessa Pharmaceuticals Raises $100 Million in Public Offering
Centessa Pharmaceuticals plc, a leading clinical-stage pharmaceutical company focused on groundbreaking treatments for patients, has successfully priced a public offering of 10,810,810 American Depositary Shares (ADSs) at $9.25 per ADS.The offering, totaling approximately $100 million in gross proceeds, will bolster Centessa’s research and development efforts as they continue to pursue transformational medicines.With an option for underwriters to purchase additional ADSs, Centessa is poised for further growth and innovation in the pharmaceutical industry.
As of the announcement, Centessa Pharmaceuticals Plc had 96.232484076433 million shares outstanding, with a current price of $9.4.The successful pricing of the public offering signals confidence in Centessa’s pipeline of potential breakthrough treatments and their commitment to advancing patient care.
The public offering is expected to close on or around April 26, 2024, pending customary closing conditions.With this infusion of capital, Centessa Pharmaceuticals is well-positioned to continue their mission of developing innovative medicines that make a meaningful impact on the lives of patients worldwide.
Comments